Louis-Bastien Weiswald is an expert in Oncology at Centre François Baclesse (France). Louis-Bastien Weiswald has authored 58 publications, the most recent in 2026. SLR score: 247 (community average: 125). How the SLR is computed.

LeadR Profile

Louis-Bastien Weiswald Centre François Baclesse France
247 ScienceLeadR Reputation 247
Network Map

Oncology

Subspecialties: Biochemistry - Gynecology - Radiotherapy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2009 - 2026

Source: PubMed

Centre François Baclesse

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 58

Citations

Citations: 2 366 1st author: 8 Last author: 5 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Complementary intra- and extracellular AGR2 activities support epithelial ovarian cancer cell aggressiveness.
PMID 42575981 — oncogenes, cells, stress, physiological, ovary, neoplasms, ovarian neoplasms, carcinoma, ovarian epithelial
Oncogene20260
Establishment of a clear cell renal cell carcinoma organoid cohort integrated into the UroCCR clinical database: A feasibility study.
PMID 42372405 — cells, feasibility studies, neoplasms, carcinoma, renal cell, organoids, therapeutics
Transl Oncol20260
UPR/ATF4/Noxa pathway overactivation through SERCA2 inhibition or ONC201 treatment combined with ABT-737 triggers apoptosis in chemoresistant ovarian cancer cells and patient-derived tumor organoids.
PMID 41896216 — cells, stress, physiological, ovary, neoplasms, organoids, ovarian neoplasms, calcium, therapeutics, apoptosis, cell death
Cell Death Dis20260
Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response.
PMID 41057919 — pharmaceutical preparations, ovary, neoplasms, drug therapy, organoids, ovarian neoplasms, genomic instability, medical oncology, chemotherapy
J Exp Clin Cancer Res20256
LncRNA MYO16-AS1 and MICAL2 axis sustains proliferation and migration in ovarian cancer cells and unveils a therapeutic vulnerability in patient-derived tumor organoids.
PMID 40822859 — cells, ovary, neoplasms, drug therapy, organoids, ovarian neoplasms, therapeutics, down-regulation, rna, long noncoding, chemotherapy
Noncoding RNA Res20250

LeadR Networks

Main global connection map